News
Affluent Medical strengthens its executive team
Michel Finance is appointed CEO.Executive team is strengthened with the appointment of:Daniele Zanotti (the former CEO) as Chief Technology and Innovation Officer leading technology developments and the execution of programs,Professor François...
Affluent Medical releases impressive results from SCOPE 1 clinical trial validating efficacy of KARDIOZIS technology
Outstanding results from SCOPE 1 randomized, controlled, multicentric clinical trial, proving the efficacy of treating life-threatening Abdominal Aortic Aneurysm (AAA), by thrombogenic fibers embolization of the aneurysm sac when performing an...
Affluent medical secures up to eur 12m debt financing from kreos capital
EUR 12 million financing comprising three tranches of EUR 4 million straight bonds. Clearing financial path to achieve major clinical milestones in view of regulatory approvals.
Affluent Medical meets a major milestone with the first clinical trial of ARTUS
• Positive results from the first clinical study on 3 patients implanted between May and September 2018 • The implant technique, via laparoscopy and open surgery, was validated, surgical safety was also verified • Implantable in about 20 minutes...
Affluent Medical announces the successful conclusion of its OPTIMISE clinical study for KALIOS
Affluent Medical announces today the positive conclusion of its OPTIMISE first clinical study for KALIOS, its adjustable mitral repair device. KALIOS has been implanted in five patients between January and May of the current year by Prof. Martin...
Key opinion Leader event
AFFLUENT MEDICAL hosted a Key Opinion Leader event Wednesday, May 23, 2018 on New Generation Technologies for Minimally Invasive Surgery of the Mitral Valve and Abdominal Aorta.Key opinion leaders (KOLs) present were Professor Christian...
